Which is worse in pregnancy, snuff or cigarettes?

Posted by: Doctor Medical  :  Category: Health News


NEW YORK |
Wed Aug 31, 2011 2:44am EDT

NEW YORK (Reuters) – Babies born to snuff-using mothers were more likely to have breathing problems than those whose mothers smoked while pregnant, according to a Swedish study.

Snuff — ground tobacco that is high in nicotine but doesn’t generate the same additional chemicals as cigarette smoke because it’s not burned — is generally assumed to be safer than cigarettes, said lead researcher Anna Gunnerbeck, from the Karolinska Institute in Stockholm.

That’s still the case for many people, but it’s not a good option for pregnant woman, she added.

“(It) may have a little bit different effect than smoking, because smoking has the combustion products, but it’s still not safe during pregnancy,” Gunnerbeck told Reuters Health.

It’s possible the same may apply to nicotine gum and patches, which some doctors recommend to women trying to stop smoking during pregnancy, the researchers wrote in Pediatrics.

Gunnerbeck and her colleagues got their data from records of about 610,000 babies born in Sweden between 1999 and 2006. They compared information gathered from mothers when they were a few months pregnant — including about snuff and cigarette use — with babies’ hospital records.

Specifically, they were looking for a diagnosis of “apnea,” which occurs when a newborn stops breathing, sometimes accompanied by an irregular heartbeat.

One or two in every 1,000 babies born to mothers who didn’t use snuff or cigarettes developed apnea. For babies whose mothers lit up during pregnancy, that risk increased by about 50 percent.

And for those whose mothers used snuff, the rate was more than twice as high as in babies born to mothers who didn’t use any kind of tobacco.

When the researchers took into account how early babies were born — prematurity has been linked to both maternal smoking and breathing problems in newborns — smoking alone didn’t have any extra effect on the risk of apnea. But apnea was still more common when mothers used snuff, regardless of whether babies were born early or not.

Many babies with apnea will get a bit of extra care after birth and be fine, but it’s also possible that they’re more likely to have breathing problems when they’re older, including sleep apnea. Apnea may also put children at higher risk of infection later.

While snuff use is more common in Sweden than elsewhere, pregnant women in other countries may also use nicotine-containing products such as gum and patches, thinking they’re safer than smoking during pregnancy.

“They’re raising the concern that Swedish snuff, because it’s largely nicotine, can be a surrogate for nicotine replacement therapy during pregnancy, that it might have untoward effects,” said Michael Weitzman, who studies smoking in pregnancy at the New York University Medical Center.

Gunnerbeck said the study suggests that women should be urged to stop smoking without nicotine replacements during pregnancy, but added that if looking at the whole picture, smoking is generally more dangerous than using snuff.

“I think the best thing for women who smoke during pregnancy is to stop if it’s possible,” she said, adding that avoiding nicotine replacement would be best.

“(But) it’s really difficult if you have a woman who smokes a lot and can’t stop — what do you do then? Always you have to consider the cases where you need (nicotine replacement) — the women who can’t stop.” SOURCE: bit.ly/qX8QVt

(Reporting by Genevra Pittman at Reuters Health; editing by Elaine Lies)

Article source: Read More

Incoming search terms for the article:

Santarus to Present at September Investment Conferences

Posted by: Doctor Medical  :  Category: Health News

SAN DIEGO–(BUSINESS WIRE)–Santarus, Inc. (NASDAQ: SNTS), a specialty biopharmaceutical company,
today announced that Gerald T. Proehl, president and chief executive
officer, will make presentations at the following investment conferences:

  • Stifel Nicolaus Healthcare Conference on September 7, 2011, at 3:50
    p.m. Eastern time (12:50 p.m. Pacific time) at the Four Seasons Hotel
    in Boston, and
  • UBS Global Life Sciences Conference on September 20, 2011, at 3:00
    p.m. Eastern time (12:00 p.m. Pacific time) at the Grand Hyatt Hotel
    in New York.

Webcasts of these presentations will be available during the event at www.santarus.com
and will be archived and available on the website for 14 days.

About Santarus

Santarus, Inc. is a specialty biopharmaceutical company focused on
acquiring, developing and commercializing proprietary products that
address the needs of patients treated by physician specialists. The
company’s current commercial efforts are focused on GLUMETZA®
(metformin hydrochloride extended release tablets) and CYCLOSET®
(bromocriptine mesylate) tablets, which are indicated as adjuncts to
diet and exercise to improve glycemic control in adults with type 2
diabetes.

Santarus also has a diverse development pipeline, including three
investigational drugs in Phase III clinical programs: budesonide MMX®
for induction of remission of active ulcerative colitis, RHUCIN®
(recombinant human C1 inhibitor) for treatment of acute attacks of
hereditary angioedema and rifamycin SV MMX® for treatment of
travelers’ diarrhea, in addition to other earlier-stage development
programs. More information about Santarus is available at www.santarus.com.

Santarus cautions you that statements included in this press release
that are not a description of historical facts are forward-looking
statements.
The inclusion of forward-looking statements should
not be regarded as a representation by Santarus that any of its plans
will be achieved.
Actual results may differ materially from those
set forth in this release due to the risks and uncertainties inherent in
Santarus’ business, including, without limitation:
difficulties
or delays in development, testing, manufacturing and marketing of, and
obtaining and maintaining regulatory approvals for, Santarus’ products;
and other risks detailed in Santarus’ prior press releases as well as in
public periodic filings with the Securities and Exchange Commission.

You are cautioned not to place undue reliance on these
forward-looking statements, which speak only as of the date hereof. All
forward-looking statements are qualified in their entirety by this
cautionary statement and Santarus undertakes no obligation to revise or
update this news release to reflect events or circumstances after the
date hereof. This caution is made under the safe harbor provisions of
Section 21E of the Private Securities Litigation Reform Act of 1995.

Santarus® is a trademark of Santarus, Inc.
GLUMETZA® is a trademark of Biovail
Laboratories International S.r.l. licensed exclusively in the United
States to Depomed, Inc.
CYCLOSET® is a
trademark of VeroScience LLC.
MMX® is a
trademark of Cosmo Technologies Limited. RHUCIN
®
is a trademark of Pharming Group NV.

Article source: Read More

Medical Tourism Provider MediClass Launches New Website

Posted by: Doctor Medical  :  Category: Health News

RAMAT GAN, Israel–(BUSINESS WIRE)–Prominent medical tourism provider MediCLass.ru has recently launched
its new website, www.mediclass.ru.
The website presents a wealth of practical information for people
seeking to undergo medical procedures abroad, from a detailed
description of a wide variety of treatments to the specific clinics that
currently offer these particular services. Although the company
presently cooperates tightly only with Israeli medical centers and
hospitals, it will soon cater to the needs of patients who opt to seek
cure to their ailments in other countries as well.

“We create an
individual treatment plan for each patient, considering all their needs
and personal wishes.”

Medical Tourism is a term describing patients receiving medical care
across their national borders. Medical Tourism offers an alternative
solution to local healthcare costs and availability as it has proven to
be cost efficient and typically provides shorter waiting lists. Combined
with benefits, such as a possible trip abroad, medical tourism is a
convenient option to anyone looking for high quality medical care. The
list of leading medical fields featured at www.mediclass.ru
includes cardiology, orthopedics, cancer, IVF, cosmetic surgeries,
gynecology and pediatrics.

Peter Bogdanov, MediClass CEO, was quoted as saying, “Medical tourism is
a rapidly growing practice. Thousands of medical tourists travel all
over the globe to receive treatment outside their home land each year.
Services typically sought by travelers include elective procedures as
well as complex specialized surgeries such as joint replacement, cardiac
surgery, dental surgery, and cosmetic surgeries. Today, MediClass
provides a wide variety of solutions aimed at people with different
financial capabilities. From consultation services only and up to
complete package deals, including flights, accommodation, travel and all
medical aspects of treatment. We fully allow our clients to decide how
involved we become in the process.”

Ivan Mishka, a Mediclass treatment coordinator, added, “We create an
individual treatment plan for each patient, considering all their needs
and personal wishes.”

About MediClass:

Based in Israel, MediClass is a well-established medical tourism company
operating in the health industry for over five years. The company seeks
to provide a safe and affordable access to healthcare to patients all
across the planet. MediClass offers its clients information about the
various medical procedures as well as recuperation packages available.
MediClass is a privately held and owned company offering a top quality
health experience in the world’s most visited destinations.

Article source: Read More

Medivir: Financial Statement, 1 January

Posted by: Doctor Medical  :  Category: Health News

HUDDINGE, Sweden–(BUSINESS WIRE)–Regulatory News:

“Medivir’s commercial presence strengthened in the Nordics”

Medivir (STO:MVIRB)

Operating profit/loss of SEK 215.7 m

All figures for the group unless otherwise stated. Unless otherwise
stated, comparisons in this Interim Report are with the corresponding
period of2010.

Interim period (January 2011 – June 2011)

— Net sales were SEK 444.6 (35.7) m

— Profit/loss after tax amounted to SEK 220.3 (-50.3) m

— Basic and diluted earnings per share were SEK 7.37 (-2.14)

— Cash flow from operating activities amounted to SEK 230.9 (4.6) m;
cash and cash equivalents and investments in securities etc. amounted to
SEK 716.4 (462.7) m at the end of the period

Second quarter (April 2011 – June 2011)

— Net sales were SEK 322.9 (14.1) of which BioPhausia, which was
consolidated from 1 June, contributed SEK 42.4 m

— Profit/loss after tax amounted to SEK 167.4 (-24.1) m

— Basic earnings per share were SEK 5.52 (-1.01)

Business highlights in the second quarter

— Medivir’s commercial presence in the Nordics enhanced through the
acquisition of BioPhausia

— Positive interim results after 48 weeks’ treatment presented from
phase 2b ASPIRE study on TMC435 in treatment-experienced hepatitis C
genotype 1 patients

— Clinical phase 1b trial commenced on polymerase inhibitor TMC649128
in patients with chronic hepatitis C virus genotype 1 infection

— Medivir receives USD 45 m (SEK 279 m) from Meda, which acquired the
American rights to Xerese®

Post-period end highlights

— Tibotec decides to conduct a combination study on TMC435 with
Pharmasset’s PSI-7977 for hepatitis C

— TMC435 receives Fast Track designation by the FDA in the US

— BioPhausia CEO Maris Hartmanis appointed Deputy CEO and Chief
Operating Officer

— BioPhausia’s generics business, BMM Pharma AB, has been divested

“Medivir’s commercial presence strengthened in the Nordics”

CEO’s comment

A trading company at the leading edge

We continued to make major advances in all segments in the second
quarter. We took a momentous step forward to consolidate our commercial
operation through our acquisition of Swedish specialty pharmaceutical
company BioPhausia.

The acquisition of BioPhausia brings Medivir a profitable product
portfolio with a number of well-known brands such as Mollipect (cough
medicine), Citodon (analgesic), Laxabon (laxative) and Egazil (irritable
bowel). The cash flow from this portfolio and enhancement of our
commercial platform via BioPhausia’s network significantly improves our
prospects of acquiring more products for sale in the Nordics, which
complements the future flow of Medivir’s proprietary products.

BioPhausia also brings an infrastructure and platform that will
facilitate the expected launch of TMC435 for HCV patients in the
Nordics, where we’ve retained the commercial rights to the product. The
Nordic market for hepatitis C consists of some 115,000 chronically
infected patients. Of this total, some 3,000 per year are currently
treated with current SoC (standard of care). In the best case, existing
therapies cure only about 50% of the patients treated for this
life-threatening disease. In addition, current therapy has problems with
both safety and tolerability. Overall, this indicates that the Nordic
region is a valuable future market for TMC435.

Late in the period, we consolidated our financial position further by
renegotiating the terms with our commercial partner Meda on Xerese®, and
our unique cold sore (labial herpes) product. Through a sale of the
rights to Xerese® in the US, Canada and Mexico to Meda, we raised USD 45
m (SEK 279 m). This agreement will trigger a payment to AstraZeneca, the
original patentee, according to previously agreed terms. Medivir has
retained the existing global rights to Xerclear® outside the US, Canada
and Mexico. We will continue to exploit these market opportunities via
various partners.

Our hepatitis C projects

Medivir is continuing to make major advances in its hepatitis C
portfolio. Our leading CD (candidate drug), the next-generation protease
inhibitor TMC435, which is under development in partnership with Johnson
Johnson subsidiary Tibotec Pharmaceuticals, has continued to achieve
very positive results. Interim data after 48 weeks’ treatment from the
phase 2b ASPIRE study on previous null responders with chronic hepatitis
C genotype 1, demonstrated significantly higher efficacy data for TMC435
than current standard of care (SoC). Additionally, TMC435 again
demonstrated an excellent safety and tolerability profile. This is
important because treatment-related adverse events are the main reason
for the poor patient compliance with current SOC.

Medivir and Tibotec also have a sharp development focus on new
combination therapies for treating hepatitis C. Our polymerase inhibitor
TMC649128 has the potential to become a key component in forthcoming HCV
combination therapies. This is due to the compound’s high genetic
resistance barrier and anti-viral activity against several HCV
genotypes. In June, phase 1b clinical studies on TMC649128 commenced on
HCV patients. A combination study on TMC435 and TMC647055, a
non-nucleoside NS5B polymerase inhibitor developed by Tibotec
Pharmaceuticals also commenced in June.

After the end of the period, Medivir presented reports regarding the
progress of the company’s hepatitis C projects. TMC435 was granted Fast
Track designation by US regulatory authority the FDA. This is a further
validation of the strong and clear profile TMC435 demonstrated in major
phase 2 studies and in comparison with the recently approved competing
antivirals, Incivek™ and Victrelis™.

TMC435 has potential to be a cornerstone of forthcoming combination
therapies. Medivir has given its support to partner Tibotec
Pharmaceuticals’ decision to commence combination studies on TMC435 with
Pharmasset’s polymerase inhibitor PSI-7977. These phase 2b combination
studies are scheduled to commence in the year. This is corroboration of
the efforts that are made to develop new treatment methods with the aim
of improving current SoC for this serious disease.

We’re looking forward to the second half of 2011. We expect to be able
to report further results from several clinical studies that may
continue to confirm the potential of TMC435 and indicate further
advances towards our goal of becoming an integrated and profitable
specialty pharmaceutical company focusing on infectious diseases.

Ron Long,
Chief Executive Officer

This information was brought to you by Cision http://www.cisionwire.com

Article source: Read More

Taiwan hospitals fined over HIV organ transplants

Posted by: Doctor Medical  :  Category: Health News, Medication

Two prestigious Taiwanese hospitals were fined Tw$150,000 ($5,170) each for negligence which led to five patients receiving organs from an HIV positive donor, authorities said Wednesday.

The National Taiwan University Hospital and National Cheng Kung University Hospital will also face criminal charges and additional fines if their patients contract the HIV virus from the transplants, the health department said.
Read more…